Related references
Note: Only part of the references are listed.Lasmiditan for the treatment of migraine
Matilde Capi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development
Piero Barbanti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine
Bianca Raffaelli et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Triptans and migraine: advances in use, administration, formulation, and development
Amanda E. Macone et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
An Update on Non-Pharmacological Neuromodulation for the Acute and Preventive Treatment of Migraine
Francesca Puledda et al.
HEADACHE (2017)
Current and novel insights into the neurophysiology of migraine and its implications for therapeutics
Simon Akerman et al.
PHARMACOLOGY & THERAPEUTICS (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
Headache research in 2015: progress in migraine treatment
Hans-Christoph Diener et al.
LANCET NEUROLOGY (2016)
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine
Uwe Reuter et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs
Peer C. Tfelt-Hansen et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
Paul B. Rizzoli
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2014)
The International Classification of Headache Disorders, 3rd edition (beta version)
Andre Bes et al.
CEPHALALGIA (2013)
Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs
Martha B. Ramirez Rosas et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan - Basic Science in Relation to Migraine Treatment
Carl Dahlof et al.
HEADACHE (2012)
The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
Peer C. Tfelt-Hansen et al.
JOURNAL OF HEADACHE AND PAIN (2012)
Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
Markus Farkkila et al.
LANCET NEUROLOGY (2012)
mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system
Dipak V. Amrutkar et al.
PAIN (2012)
Distribution of 5-HT1B, 5-HT1D and 5-HT1F receptor expression in rat trigeminal and dorsal root ganglia neurons: Relevance to the selective anti-migraine effect of triptans
J. D. Classey et al.
BRAIN RESEARCH (2010)
5-Hydroxyptryptamine IF (5-HTIF) receptor agonism. A possible new treatment principle for acute migraine attacks
Jes Olesen
CEPHALALGIA (2010)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
Acute treatment of migraine with the selective 5-HTIF receptor agonist lasmiditan - A randomised proof-of-concept trial
Michel D. Ferrari et al.
CEPHALALGIA (2010)
The vascular theory of migrainea great story wrecked by the facts
Peter J. Goadsby
BRAIN (2009)
Colocalization of 5-HT1F receptor and glutamate in neurons of the vestibular nuclei in rats
Seong-Ki Ahn et al.
NEUROREPORT (2009)
Colocalization of 5-HT1F receptor and calcitonin gene-related peptide in rat vestibular nuclei
Seong-Ki Ahn et al.
NEUROSCIENCE LETTERS (2009)
History of methysergide in migraine
P. J. Koehler et al.
CEPHALALGIA (2008)
History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward
P. C. Tfelt-Hansen et al.
CEPHALALGIA (2008)
Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey
Hyo-Jin Jeong et al.
MOLECULAR PAIN (2008)
Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine
Joel R. Saper et al.
HEADACHE (2006)
Expression mapping of 5-HT1 serotonin receptor subtypes during fetal and early postnatal mouse forebrain development
A. Bonnin et al.
NEUROSCIENCE (2006)
Neurogenic inflammation and migraine: Implications for therapeutics
SJ Peroutka
MOLECULAR INTERVENTIONS (2005)
[3H]LY334370, a novel radioligand for the 5-HT1F receptor.: II.: Autoradiographic localization in rat, guinea pig, monkey and human brain
VL Lucaites et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2005)
5-HT1 Receptors
Laurence Lanfumey et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2004)
Double-blind clinical trials of oral triptans vs other classes of acute migraine medication -: a review
RB Lipton et al.
CEPHALALGIA (2004)
Ergotamine and dihydroergotamine: History, pharmacology, and efficacy
SD Silberstein et al.
HEADACHE (2003)
Evidence for serotonin (5-HT)(1B), 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input
PJ Goadsby et al.
NEUROSCIENCE (2003)
Features of medication overuse headache following overuse of different acute headache drugs
V Limmroth et al.
NEUROLOGY (2002)
5-Hydroxytryptamine1B/1D and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis
DD Mitsikostas et al.
CEPHALALGIA (2002)
Co-localization of 5-HT1B/1B/1F receptors and glutamate in trigeminal ganglia in rats
QP Ma
NEUROREPORT (2001)
No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries:: similarity with human coronary artery
I Bouchelet et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
